Tamara A. (Seymour) Favorito

Mrs. Favorito has served as director and chair of the audit committee since August 2021 and as the chair of the board of Zevra Therapeutics since May 2023. Mrs. Favorito has more than 30 years of life sciences industry experience including 20 years as a chief financial officer.

Her extensive experience includes leading multiple private and public financings, M&A transactions as well as leading the finance, investor relations, human resources, administration and managed care functions.

She currently serves as a board member and audit committee chair of Artelo Biosciences, Inc. and Kintara Therapeutics, Inc., both publicly traded clinical-development stage companies. Mrs. Favorito served on the board of directors of Beacon Discovery, Inc. from 2018 until their acquisition in March 2021.

Mrs. Favorito was Interim CFO of Immunic, Inc., a publicly traded clinical-stage drug development company in 2019. She served as CFO of Signal Genetics, Inc. (now Viridian Therapeutics, Inc.), a publicly traded molecular diagnostics company, from 2014 to 2017, HemaQuest Pharmaceuticals, Inc., a venture-backed clinical-stage drug development company, from 2010 to 2014 and Favrille, Inc. (now MMR Global, Inc.), a publicly traded clinical-stage drug development company, from 2001 to 2009.

Earlier in her career, she spent eight years in public accounting with Deloitte & Touche LLP and PricewaterhouseCoopers LLP. Mrs. Favorito is a Certified Public Accountant (inactive).

She received an MBA, emphasis in finance, from Georgia State University, and a BBA, emphasis in accounting, from Valdosta State University.